Table 4.
Treatments and complications
| Finnish-type disease N = 33 |
Non-Finnish-type without syndrome N = 26 |
Non-Finnish-type with syndrome N = 24 |
|
|---|---|---|---|
| Medicationsa | |||
| Steroids |
3/29 (NR, 3) |
18/25 (NR, 11; PR, 4; CR, 3) |
8/24 (NR, 7; PR, 1) |
| Immunosuppressants |
3/28 (CSA, NR, 2; PR, 1) |
12/25 (NR, 1; PR, 2; CR, 9) |
4/24 (NR, 4) |
| Immunosuppressant therapy by response |
CSA, NR CSA + MZB, NR CSA, PR |
CSA + TAC + MZB, NR CSA, PR (n = 2) CSA, CR (n = 4) MZB, CR CSA + MZB, CR CSA + CP, CR CSA + MMF + RTX, CR CSA + MZB + RTX, CR |
CSA, NR (n = 4) |
| Complicationsa | |||
| Thrombosis | 5/32 | 1/26 | 1/24 |
| Infections | 19/32 | 7/26 | 9/24 |
| Other | 8/32 | 9/26 | 11/24 |
Abbreviations: CP cyclophosphamide, CR complete remission, CSA cyclosporine, MMF mycophenolate mofetil, MZB mizoribine, NR no response, PR partial remission, RTX rituximab, TAC tacrolimus
aThe denominator represents the number of patients for whom responses regarding medications and complications were obtained